Status:
WITHDRAWN
Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection
Lead Sponsor:
Ochsner Health System
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Patients who meet inclusion criteria will be randomized into treatment vs control group. Treatment groups will undergo Hyperbaric Oxygen Therapy (HBOT) and compared to the control group.
Detailed Description
After enrollment, patients will be randomized into treatment vs control group. Both populations will receive the same inpatient medical treatment. All patients in the treatment group will undergo hype...
Eligibility Criteria
Inclusion
- Adult inpatients \>18 years old
- Positive PCR COVID-19 testing
- CT evidence of interstitial opacity
- Oxygen saturation \<90% on room air
- pO2 = 55-70.
Exclusion
- Increased oxygen requirements
- Hemodynamic instability (MAP\<65)
- Bradycardia (HR\<50)
- History of seizure disorder
- Pneumothorax
- GFR\<30
- Hemodialysis
- Refractory anxiety/claustrophobia
- Current pregnancy
- Uncorrectable hypoglycemia
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04343183
Start Date
April 1 2020
End Date
June 1 2020
Last Update
April 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ochsner Medical Center
New Orleans, Louisiana, United States, 70121